Regulatory PathRegulatory requirements compared

Active substances

Loperamide + Simeticone

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Imodium Plus Caplets125,2 mg,mgTablet · Oral use12 BlisterSAR 25.70NCE · OTCMCNEIL PRODUCTS LIMITEDValid

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
IMODIUM MULTI-SYMPTOM RELIEF2MG;125MGtablet · oralKENVUE BRANDSOver-the-counter30 Nov 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralPERRIGO R AND DOver-the-counter5 Sep 2018
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralAUROBINDO PHARMA LTDOver-the-counter14 Dec 2020
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralGUARDIAN DRUGOver-the-counter27 May 2021
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralHETERO LABS LTD VOver-the-counter17 Jun 2021
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralBIONPHARMAOver-the-counter10 Sep 2021
IMODIUM MULTI-SYMPTOM RELIEF2MG;125MGtablet, chewable · oralJ AND J CONSUMER INCDiscontinued26 Jun 1997
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet, chewable · oralPERRIGODiscontinued30 Aug 2002
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralSUN PHARM INDS LTDDiscontinued6 Sep 2006
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE2MG;125MGtablet · oralGRANULESDiscontinued29 Aug 2022

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
IMODIUM COMPLETE02245185125 MG; 2 MGTABLET · ORALKENVUE CANADA INC.

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffLoperamide 2mg / Simeticone 125mg tablets£3.396 tablet1 Oct 2026
NHS Drug TariffLoperamide 2mg / Simeticone 125mg tablets£5.9412 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.